| Filed On | Filing |
|---|---|
| 12 Nov 2026 | SCHEDULE 13G/A |
| 03 Nov 2026 |
Form 4: Apuli Maricel, Chief Accounting Officer
Sold 2,000 shares ($146K) |
| 29 Oct 2026 | 10-Q |
| 29 Oct 2026 |
8-K: Results of Operations and Financial Condition
- $353.2 million in total third quarter revenues, primarily comprised of $253.2 million of U.S. Attruby net product revenue (up approximately $31 million sequentially and $145 million year over year). Loss from operations was $11.6 milli... |
| 27 Oct 2026 | SCHEDULE 13G |
| 13 Oct 2026 |
8-K: Other Events
- Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Priority Review by the FDA underscores the significant unmet need for an oral targeted therapeutic option for children with achondroplasia |
| 21 Sep 2026 |
Form 4: Kumar Neil, Director
Sold 10,000 shares ($691K) |
| 31 Aug 2026 |
8-K: Other Events
BridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans |
| 20 Aug 2026 |
Form 4: Kumar Neil, Director
Sold 34,980 shares ($2.89M) · Sold 10,000 shares ($840K) |
| 19 Aug 2026 | 144 |
| 18 Aug 2026 |
Form 4: Trimarchi Thomas, President and CFO
Gave up 22,781 shares to cover exercise price or tax ($1.82M) |
| 18 Aug 2026 |
Form 4: Kumar Neil, Director
Received 71,217 shares by exercise or conversion · Gave up 36,237 shares to cover exercise price or tax ($2.89M) |
| 18 Aug 2026 |
Form 4: Apuli Maricel, Chief Accounting Officer
Gave up 4,714 shares to cover exercise price or tax ($376K) |
| 18 Aug 2026 | 144 |
| 17 Aug 2026 | SCHEDULE 13D/A |
| 17 Aug 2026 | 144 |
| 17 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
As representatives (the “Representatives”) of the several underwriters |
| 14 Aug 2026 | 424B7 |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition
- $243.7 million in total second quarter revenues, primarily comprised of $222.4 million of U.S. Attruby® net product revenue, with growth led by the treatment-naïve segment as physicians increasingly start and keep patients on Attruby |
Loading...